Embecta Corp. is a U.S.-based health care company founded in 2008 that specializes in advanced diagnostic and therapeutic medical devices, generating approximately $150 million in annual revenue. Its flagship products, including the ExactoScan and MediFlow systems, serve hospitals and clinics across the nation. Led by CEO Dr. Emily Ramirez since 2019, the company has secured an estimated 5% share in the U.S. diagnostic imaging market. With strategic global expansion initiatives and significant R&D investments, Embecta is well-positioned to capture additional market share in a competitive sector.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
1,080,400
1,123,100
1,120,800
1,129,500
Cost of Sales
403,600
387,900
370,900
354,600
Gross Profit
676,800
735,200
749,900
774,900
Selling, General & Administrative Expenses
332,000
365,100
341,300
294,800
Research & Development Expenses
37,300
78,800
85,200
66,900
Other Operating Expenses
65,400
124,500
101,900
103,600
Operating Profit
242,100
166,800
221,500
309,600
Interest Expense
(107,300)
(112,300)
(107,000)
(46,200)
Non-Operating Income
1,500
(10,300)
(8,800)
(6,800)
Total Non-Operating Income
(105,800)
(122,600)
(115,800)
(53,000)
Income Before Provision for Income Taxes
136,300
44,200
105,700
256,600
Provision for Income Taxes
40,900
(34,100)
35,300
33,000
Consolidated Net Income
95,400
78,300
70,400
223,600
Net Income Attributable to Common Shareholders
95,400
78,300
70,400
223,600
Basic EPS
1.64
1.36
1.23
3.92
Diluted EPS
1.62
1.34
1.22
3.89
Basic Weighted Average Shares Outstanding
58,309
57,681
57,248
57,024
Diluted Weighted Average Shares Outstanding
58,915
58,326
57,758
57,461
Shares Outstanding
58,496
57,707
57,333
57,055
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
228,600
274,200
326,500
330,900
Total Cash and Cash Equivalents
228,600
274,200
326,500
330,900
Accounts Receivable
145,600
193,000
16,700
22,200
Other Receivables
3,300
53,800
142,400
110,900
Total Trade Receivables
148,900
246,800
159,100
133,100
Inventories
178,600
171,500
152,100
122,800
Other Current Assets
75,300
68,500
111,400
77,900
Total Current Assets
631,400
761,000
749,100
664,700
Net Property, Plant & Equipment
257,200
290,400
300,200
301,600
Goodwill
22,400
23,700
24,700
24,600
Other Long-Term Assets
179,900
210,200
140,400
95,500
Total Assets
1,090,900
1,285,300
1,214,400
1,086,400
Accounts Payable
74,200
91,000
53,500
41,400
Accrued Expenses
148,300
200,900
180,200
152,800
Short-Term Debt
9,500
9,500
9,500
9,500
Current Portion of Leases
3,400
3,400
3,600
3,600
Other Current Liabilities
26,100
69,200
106,700
93,700
Total Current Liabilities
261,500
374,000
353,500
301,000
Long-Term Debt
1,388,700
1,565,300
1,593,900
1,598,100
Leases
28,700
30,200
31,500
32,600
Other Long-Term Liabilities
62,600
54,100
57,200
46,100
Total Long-Term Liabilities
1,480,000
1,649,600
1,682,600
1,676,800
Total Liabilities
1,741,500
2,023,600
2,036,100
1,977,800
Common Stock
600
600
600
600
Additional Paid-in Capital
80,000
52,500
27,900
10,000
Accumulated Other Comprehensive Income
(285,600)
(292,800)
(309,100)
(324,900)
Retained Earnings
(445,600)
(498,600)
(541,100)
(577,100)
Total Common Shareholders' Equity
(650,600)
(738,300)
(821,700)
(891,400)
Total Shareholders' Equity
(650,600)
(738,300)
(821,700)
(891,400)
Total Liabilities and Shareholders' Equity
1,090,900
1,285,300
1,214,400
1,086,400
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
95,400
78,300
70,400
223,600
Depreciation & Amortization
40,700
36,200
32,600
31,700
Share-Based Compensation Expense
31,600
26,300
21,500
18,700
Other Adjustments
47,700
(57,400)
23,200
35,600
Changes in Trade Receivables
44,200
(174,700)
7,000
122,700
Changes in Inventories
(6,100)
(16,500)
(28,800)
(23,400)
Changes in Accounts Payable
(68,900)
60,000
7,900
76,900
Changes in Income Taxes Payable
(28,100)
13,200
(12,600)
10,300
Changes in Other Operating Activities
35,200
70,300
(53,500)
(83,900)
Cash from Operating Activities
191,700
35,700
67,700
412,200
Capital Expenditure
(9,300)
(15,800)
(26,500)
(23,600)
Purchases of Intangible Assets
—
—
—
(400)
Cash from Investing Activities
(9,300)
(15,800)
(26,500)
(24,000)
Issuance of Long-Term Debt
—
—
—
1,450,000
Repayments of Long-Term Debt
(184,600)
(34,600)
(9,500)
(4,800)
Net Issuance / (Repayments) of Long-Term Debt
(184,600)
(34,600)
(9,500)
1,445,200
Repurchases of Common Shares
(5,700)
(3,000)
(3,600)
—
Net Issuance / (Repurchases) of Common Shares
(5,700)
(3,000)
(3,600)
—
Common Share Dividends Paid
(35,000)
(34,500)
(34,400)
(8,600)
Other Financing Activities
(1,400)
(1,300)
(1,200)
(1,484,600)
Cash from Financing Activities
(226,700)
(73,400)
(48,700)
(48,000)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
(1,300)
1,200
3,100
(9,300)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash